1. The risks of hepatocellular carcinoma and variceal bleeding after HCV eradication with direct-acting antiviral therapy: a propensity score analysis
- Author
-
Preda Carmen, Dimache Mihaela, Girleanu Irina, M Manolache, Iacob Speranta, Cojocariu Camelia, Miftode Egidia, Huiban Laura, Muzica Cristina Maria, Trifan Anca, Carol Stanciu, Catalin Sfarti, Tudor Cuciureanu, Cijevschi Prelipcean Cristina, Singeap Ana Maria, Gheorghe Liana, Pop Corina, Mihai Catalina, Ciortescu Irina, and Stefanescu Gabriela
- Subjects
medicine.medical_specialty ,Dasabuvir ,business.industry ,Ribavirin ,General Medicine ,medicine.disease ,Gastroenterology ,digestive system diseases ,Ombitasvir ,chemistry.chemical_compound ,Esophageal varices ,chemistry ,Paritaprevir ,Hepatocellular carcinoma ,Internal medicine ,medicine ,Ritonavir ,Decompensation ,business ,medicine.drug - Abstract
The combination paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD), which achieves a high sustained virologic response (SVR) rate and few side effects, has dramatically changed the outcome of hepatitis C virus (HCV) infection. The risk of hepatocellular carcinoma (HCC) and variceal bleeding in patients treated with interferon (IFN)-free direct-acting antivirals (DAAs) is unknown. The aim of this prospective study was to evaluate the rate of HCC and variceal bleeding and identify prognostic factors for decompensation/complications in HCV-1b-infected patients with compensated liver cirrhosis following treatment with PrOD with or without ribavirin. Material and methods: A total of 483 HCV patients received PrOD treatment. Patients with a history of HCC were excluded from the study. Prior antiviral therapy was identified in 59% of patients. Patient data were collected at baseline, at the end of treatment (EoT), at 3 months after EOT (SVR) and during an 18-month surveillance period. Patients were divided into two age groups
- Published
- 2021